SCHEMBL4138228

SCHEMBL4138228

COC(=O)c1cc(-c2ccc(C=C3SC(Nc4ccc(C(Br)C(=O)O)c(F)c4)=NC3=O)c(F)c2)ccc1N

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 5/20 0.32
MEN1 O00255 4/20 0.32
KMT2A Q03164 4/20 0.32
HPGD P15428 3/20 0.32
MCL1 Q07820 1/20 0.32
ALDH1A1 P00352 2/20 0.31
MAPT P10636 2/20 0.31
KDM4E B2RXH2 1/20 0.31
NPC1 O15118 1/20 0.31
LMNA P02545 1/20 0.31
RECQL P46063 1/20 0.31
RAB9A P51151 1/20 0.31
HTT P42858 1/20 0.31
ALOX5 P09917 1/20 0.30
THRB P10828 1/20 0.30
CHEK1 O14757 1/20 0.30
DAPK3 O43293 1/20 0.30
PRKD3 O94806 1/20 0.30
PIM1 P11309 1/20 0.30
MAPK8 P45983 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4138226 1.00 TDP1 (0.32) TDP1MEN1KMT2AHPGDMCL1
SCHEMBL4634371 0.83 TDP1 (0.35) TDP1MEN1KMT2AHPGDMCL1
SCHEMBL4136975 0.81 MEN1 (0.33) TDP1MEN1KMT2AHPGDMCL1
SCHEMBL4136968 0.81 MEN1 (0.33) TDP1MEN1KMT2AHPGDMCL1
SCHEMBL4120885 0.81 HPGD (0.34) TDP1MEN1KMT2AHPGDMCL1
SCHEMBL4120886 0.81 HPGD (0.34) TDP1MEN1KMT2AHPGDMCL1
SCHEMBL4635136 0.73 KMT2A (0.33) TDP1MEN1KMT2AHPGDALDH1A1
SCHEMBL4137074 0.73 ALOX5 (0.36) MAPTALOX5
SCHEMBL4138804 0.73 PTGS2 (0.32) HPGDALDH1A1MAPTKDM4E
SCHEMBL4128497 0.72 PTP4A3 (0.47) TDP1MEN1KMT2AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ TDP1 1151/4885MEN1 4075/4885KMT2A 2895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.